Name: ABIONYX PHARMA SA (ABNX) Stock
Brand: ABIONYX PHARMA SA
Rating: 5.5 (3 reviews)

Question 1

What does ABIONYX PHARMA SA do?

Accepted Answer

ABIONYX Pharma SA engages in the in discovery and development of novel therapies for patients without existing or effective treatments. The company is headquartered in Balma, Occitanie and currently employs 51 full-time employees. The company went IPO on 2015-03-30. The Company’s product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The firm is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.

Question 2

Can you provide the latest stock price for ABIONYX PHARMA SA?

Accepted Answer

The current stock price of ABNX.PA is 3.865 EUR. The price increased by 6.04% in the last trading session.

Question 3

Does ABNX stock pay dividends?

Accepted Answer

ABNX.PA does not pay a dividend.

Question 4

How is the ChartMill rating for ABIONYX PHARMA SA?

Accepted Answer

ABNX.PA has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.

Question 5

How is the market expecting ABNX stock to perform?

Accepted Answer

8 analysts have analysed ABNX.PA and the average price target is 10.97 EUR. This implies a price increase of 183.7% is expected in the next year compared to the current price of 3.865.

Question 6

Can you provide the PE ratio for ABNX stock?

Accepted Answer

ABIONYX PHARMA SA (ABNX.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.14).

ABIONYX PHARMA SA (ABNX.PA) Stock Price, Forecast & Analysis

ABNX.PA Latest News, Press Relases and Analysis